跳至主要内容
临床试验/ISRCTN77382043
ISRCTN77382043进行中(未招募)3 期

Preventing and delaying the development of diabetes in Africa: a randomised placebo-controlled double-blind phase III trial of metformin in people living with HIV-infection and pre-diabetes.

niversity College London0 个研究点目标入组 2,100 人开始时间: 2020年7月9日最近更新:

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
2,100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current participant inclusion criteria as of 12/12/2022:
  • 1. Adult HIV-positive persons on antiretroviral therapy (ART) for at least 6 months and considered stable on treatment (i.e. in regular attendance for care). Considered by the clinical team to be in routine care with a plasma viral load of less than 1000 copies per ml taken within the last 12 months.
  • 2. Either impaired fasting glucose (=6.1 to =6.9 mmol/L) and/or impaired glucose tolerance at 2 hours (=7.8 to <11.10 mmol/L)
  • 3. Planning to remain in the area for > 12 months
  • 4. Written informed consent
  • Previous participant inclusion criteria:
  • 1. HIV-positive and stable on the same antiretroviral therapy for at least 6-months
  • 2. Attending the HIV clinic regularly for at least 6 months
  • 3. Impaired fasting glucose of between 6.1 to 6.9 mmol/L and/or impaired glucose tolerance at 2 hours of 7.8 to 11.10 mmol/L
  • 4. Planning to remain in the area for > 1 year
  • 5. Willing to provide written informed consent

排除标准

  • Current participant exclusion criteria as of 12/12/2022:
  • 1. Pregnant women
  • 2. Patients who were participants of the META Phase II study
  • 3. Renal disease or renal dysfunction (eGFR<45)
  • 4. Signs and symptoms of any form of acute metabolic acidosis including lactic acidosis and diabetic ketoacidosis
  • 5. Other acute conditions with:
  • 5.1. The potential to alter renal function including dehydration, severe infection or shock
  • 5.2. The potential to cause tissue hypoxia including decompensated heart failure, respiratory failure, recent myocardial infarction, shock
  • 6. Congestive heart failure requiring pharmacological treatment
  • 7. Clinical evidence of liver disease
  • 8. Evidence of alcoholism or acute alcohol intoxication
  • 9. Known hypersensitivity to metformin or any excipients associated with the preparation (in this case: Magnesium stearate, sodium carboxymethylcellulose, hypromellose)
  • 10. Other acute conditions requiring hospital admission or emergency clinical intervention, including blood pressure >180/110 mmHg, haemoglobin<6.5g/dL for women or haemoglobin <7.0g/dL for men (grade 3); white cell count <1.5 x 109 cells/mm3(grade 3) and any baseline liver function derangements at grade 4 according to DAIDS criteria.
  • Previous participant exclusion criteria:
  • 1. Pregnant women
  • 2. Renal disease or renal dysfunction (eGFR < 45)
  • 3. Signs and symptoms of any form of acute metabolic acidosis including lactic acidosis and diabetic ketoacidosis
  • 4. Other acute conditions with:
  • 4.1. The potential to alter renal function including: dehydration, severe infection or shock
  • 4.2. The potential to cause tissue hypoxia including decompensated heart failure, respiratory failure, recent myocardial infarction, shock
  • 5. Congestive heart failure requiring pharmacological treatment
  • 6. Clinical evidence of liver disease
  • 7. Evidence of alcoholism or acute alcohol intoxication
  • 8. Known hypersensitivity to metformin or any excipients associated with the preparation (in this case: Magnesium stearate, sodium carboxymethylcellulose, hypromellose)
  • 9. Other acute conditions requiring hospital admission

研究者

发起方
niversity College London

相似试验